Recursion Pharmaceuticals' partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments ...

The CISCE has released the ISC Class 12 Computer Science syllabus for the 2026-27 board exam, emphasizing algorithmic problem-solving and future computing trends.It details theory on Boolean algebra, ...

Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while ...

Management lowered 2026 full-year cash operating expense guidance to $375 million, representing a nearly 40% reduction from 2024 pro forma expenses through improved ROI on technology. Additional Phase ...

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar ...

Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Lilian Weng, who built OpenAI’s safety team, is rejoining the lab to lead recursive self-improvement research — the ...